{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:39:21Z","timestamp":1792373961859,"version":"4.4.0"},"reference-count":23,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To compare the segment\u2010based diagnostic performance of multiparametric magnetic resonance imaging (mpMRI), Gallium\u201068\u2010prostate\u2010specific membrane antigen\u2010positron emission tomography\/computed tomography (\n                      <jats:sup>68<\/jats:sup>\n                      Ga\u2010PSMA\u2010PET\/CT), for detecting histopathologically confirmed prostate cancer (PCa).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>This analysis included 97 men from the prospective, interventional, phase II DEPROMP (DEtection rate of clinically significant PROstate cancer by mpMRI and PSMA\u2010PET\/CT fusion biopsy) trial who underwent radical prostatectomy with whole\u2010mount histopathological evaluation. All participants received mpMRI and PSMA\u2010PET\/CT prior to biopsy. The mpMRI was interpreted according to Prostate Imaging\u2010Reporting and Data System (PI\u2010RADS) version(v)2.1, and PSMA\u2010PET\/CT according to Prostate Cancer Molecular Imaging Standardised Evaluation (PROMISE) molecular imaging Tumour\u2010Node\u2010Metastasis (miTNM) criteria. The prostate was divided into 36 anatomical segments based on the PI\u2010RADS v2.1 sector map. Each segment was correlated with histopathological findings from prostatectomy specimens. For each imaging modality, detection rates, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) were calculated at the segment level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3492 prostate segments were analysed. Detection rates were 74.1% (95% confidence interval [CI] 72.6\u201375.5) for mpMRI, 72.2% (95% CI 70.6\u201373.6) for PSMA\u2010PET\/CT, and 79.1% (95% CI 77.7\u201380.4) for the combined use of mpMRI and PSMA\u2010PET\/CT. Sensitivity and specificity were 13.4% and 97.3% for mpMRI, 18.5% and 92.7% for PSMA\u2010PET\/CT, and 25.8% and 90.5% for combined mpMRI and PSMA\u2010PET\/CT, respectively. Threshold\u2010based receiver operating characteristic analyses yielded an AUC of 0.62 (95% CI 0.54\u20130.69) for PI\u2010RADS, 0.68 (95% CI 0.63\u20130.74) for maximum standardised uptake value, and 0.69 (95% CI 0.65\u20130.74) for molecular imaging PSMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>At the segment level, mpMRI and PSMA\u2010PET\/CT showed comparable diagnostic accuracy with high specificity but limited sensitivity. Their combination improved sensitivity and overall detection performance, underscoring the complementary value of structural and molecular imaging for lesion localisation and precision management in PCa.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.70497","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:42:46Z","timestamp":1792370566000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Segment\u2010based comparison of\n                    <scp>multiparametric MRI<\/scp>\n                    , Gallium\u201068\u2010\n                    <scp>PSMA<\/scp>\n                    \u2010\n                    <scp>PET<\/scp>\n                    \/\n                    <scp>CT<\/scp>\n                    and combined imaging with histopathology in prostate cancer"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1651-1595","authenticated-orcid":false,"given":"Clarissa J.","family":"Schmidt","sequence":"first","affiliation":[{"name":"Department of Urology and Pediatric Urology University Hospital Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7349-318X","authenticated-orcid":false,"given":"Marit","family":"Bernhardt","sequence":"additional","affiliation":[{"name":"Institute of Pathology University Hospital Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Kristiansen","sequence":"additional","affiliation":[{"name":"Institute of Pathology University Hospital Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-0145","authenticated-orcid":false,"given":"Florian C.","family":"Gaertner","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine University Hospital Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0097-2296","authenticated-orcid":false,"given":"Barbara","family":"Kreppel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine University Hospital Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Essler","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine University Hospital Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7715-4636","authenticated-orcid":false,"given":"Julian A.","family":"Luetkens","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology University Hospital Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Attenberger","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Anspach","sequence":"additional","affiliation":[{"name":"Department of Urology Johanniter Hospital Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten\u2010Henning","family":"Ohlmann","sequence":"additional","affiliation":[{"name":"Department of Urology Johanniter Hospital Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9171-4225","authenticated-orcid":false,"given":"Stefan","family":"Hauser","sequence":"additional","affiliation":[{"name":"Department of Urology and Pediatric Urology University Hospital Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7526-0857","authenticated-orcid":false,"given":"J\u00f6rg","family":"Ellinger","sequence":"additional","affiliation":[{"name":"Department of Urology GFO Hospital Troisdorf  Troisdorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ritter","sequence":"additional","affiliation":[{"name":"Department of Urology and Pediatric Urology University Hospital Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8213-9975","authenticated-orcid":false,"given":"Philipp","family":"Krausewitz","sequence":"additional","affiliation":[{"name":"Department of Urology and Pediatric Urology University Hospital Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,18]]},"reference":[{"key":"e_1_2_14_2_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","journal-title":"CA A Cancer J Clinicians"},{"key":"e_1_2_14_3_1","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13162697","article-title":"Prostate MRI and PSMA\u2010PET in the primary diagnosis of prostate cancer","volume":"13","author":"Cereser L","year":"2023","journal-title":"Diagnostics"},{"key":"e_1_2_14_4_1","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI\u2010targeted or standard biopsy for prostate\u2010cancer diagnosis","volume":"378","author":"Kasivisvanathan V","year":"2018","journal-title":"N Engl J Med"},{"key":"e_1_2_14_5_1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi\u2010parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed HU","year":"2017","journal-title":"Lancet"},{"key":"e_1_2_14_6_1","first-page":"147","article-title":"Discordance between prostate MRI and PSMA\u2010PET\/CT: the next big challenge for primary prostate tumor assessment?","volume":"45","author":"Woo S","year":"2025","journal-title":"Eur Radiol"},{"key":"e_1_2_14_7_1","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","article-title":"Combining PSMA\u2010PET and PROMISE to re\u2010define disease stage and risk in patients with prostate cancer: a multicentre retrospective study","volume":"25","author":"Karpinski MJ","year":"2024","journal-title":"Lancet Oncol"},{"key":"e_1_2_14_8_1","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jamaoncol.2024.3196","article-title":"Fluorine\u201018 prostate\u2010specific membrane antigen\u20131007 PET\/CT vs multiparametric MRI for locoregional staging of prostate cancer","volume":"10","author":"Mookerji N","year":"2024","journal-title":"JAMA Oncol"},{"key":"e_1_2_14_9_1","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/MNM.0000000000001743","article-title":"Histopathology\u2010validated lesion detection rates of clinically significant prostate cancer with mpMRI, [68Ga]PSMA\u201011\u2010PET and [11C]acetate\u2010PET","volume":"44","author":"Sandgren K","year":"2023","journal-title":"Nucl Med Commun"},{"key":"e_1_2_14_10_1","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate\u2010specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","author":"Emmett L","year":"2021","journal-title":"Eur Urol"},{"key":"e_1_2_14_11_1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2967\/jnumed.121.262398","article-title":"Head\u2010to\u2010head comparison of68 Ga\u2010PSMA\u201011 PET\/CT and mpMRI with a histopathology gold standard in the detection, intraprostatic localization, and determination of Local extension of primary prostate cancer: results from a prospective single\u2010center imaging trial","volume":"63","author":"Sonni I","year":"2022","journal-title":"J Nucl Med"},{"key":"e_1_2_14_12_1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41391-018-0048-7","article-title":"68Ga\u2010PSMA PET\/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology","volume":"21","author":"Berger I","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"e_1_2_14_13_1","doi-asserted-by":"crossref","first-page":"10963","DOI":"10.1038\/s41598-020-67385-9","article-title":"Comparison of 68Ga\u2010PSMA\u2010617 PET\/CT with mpMRI for the detection of PCa in patients with a PSA level of 4\u201320 ng\/ml before the initial biopsy","volume":"10","author":"Li Y","year":"2020","journal-title":"Sci Rep"},{"key":"e_1_2_14_14_1","article-title":"Impact of initial prostate\u2010specific membrane antigen PET\/CT staging and prostate\u2010specific membrane antigen\u2013targeted biopsy on treatment decisions in prostate cancer: results from the phase 2 DEPROMP trial","volume":"12","author":"Krausewitz P","year":"2025","journal-title":"J Nucl Med"},{"key":"e_1_2_14_15_1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13063-023-07197-0","article-title":"DEPROMP trial: the additive value of PSMA\u2010PET\/CT\u2010guided biopsy for prostate cancer management in biopsy na\u00efve men\u2014study protocol for a randomized trial","volume":"24","author":"Krausewitz P","year":"2023","journal-title":"Trials"},{"key":"e_1_2_14_16_1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA\u2010ligand PET\/CT","volume":"59","author":"Eiber M","year":"2018","journal-title":"J Nucl Med"},{"key":"e_1_2_14_17_1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey B","year":"2019","journal-title":"Eur Urol"},{"key":"e_1_2_14_18_1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU\u2010EANM\u2010ESTRO\u2010ESUR\u2010SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet N","year":"2021","journal-title":"Eur Urol"},{"key":"e_1_2_14_19_1","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma","volume":"44","author":"Leenders GJLH","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"e_1_2_14_20_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13550-022-00881-3","article-title":"Comparison of 68Ga\u2010PSMA PET\/CT and multiparametric MRI for the detection of low\u2010 and intermediate\u2010risk prostate cancer","volume":"12","author":"Zhou C","year":"2022","journal-title":"EJNMMI Res"},{"key":"e_1_2_14_21_1","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2967\/jnumed.118.221010","article-title":"Combination of68 Ga\u2010PSMA PET\/CT and multiparametric MRI improves the detection of clinically significant prostate cancer: a lesion\u2010by\u2010lesion analysis","volume":"60","author":"Chen M","year":"2019","journal-title":"J Nucl Med"},{"key":"e_1_2_14_22_1","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.euo.2023.11.008","article-title":"Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga\u2010PSMA\u201011 positron emission tomography\/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer","volume":"7","author":"Buteau JP","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"e_1_2_14_23_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1148\/radiol.2291010898","article-title":"Receiver operating characteristic curves and their use in radiology","volume":"229","author":"Obuchowski NA","year":"2003","journal-title":"Radiology"},{"key":"e_1_2_14_24_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41824-023-00182-5","article-title":"Accuracy of combined multi\u2010parametric MRI and PSMA PET\u2010CT in diagnosing localized prostate cancer: newer horizons for a biopsy\u2010free pathway","volume":"7","author":"Sharma AP","year":"2023","journal-title":"Eur J Hybrid Imag"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70497","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.70497","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:42:49Z","timestamp":1792370569000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.70497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,18]]},"references-count":23,"alternative-id":["10.1111\/bju.70497"],"URL":"https:\/\/doi.org\/10.1111\/bju.70497","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,18]]},"assertion":[{"value":"2026-10-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bju.70497"}}